| Literature DB >> 28591638 |
E Danielle Dean1, Mingyu Li2, Nripesh Prasad3, Scott N Wisniewski1, Alison Von Deylen1, Jason Spaeth4, Lisette Maddison4, Anthony Botros4, Leslie R Sedgeman4, Nadejda Bozadjieva5, Olga Ilkayeva6, Anastasia Coldren1, Greg Poffenberger1, Alena Shostak1, Michael C Semich1, Kristie I Aamodt1, Neil Phillips1, Hai Yan7, Ernesto Bernal-Mizrachi8, Jackie D Corbin4, Kasey C Vickers9, Shawn E Levy3, Chunhua Dai1, Christopher Newgard6, Wei Gu10, Roland Stein4, Wenbiao Chen4, Alvin C Powers11.
Abstract
Decreasing glucagon action lowers the blood glucose and may be useful therapeutically for diabetes. However, interrupted glucagon signaling leads to α cell proliferation. To identify postulated hepatic-derived circulating factor(s) responsible for α cell proliferation, we used transcriptomics/proteomics/metabolomics in three models of interrupted glucagon signaling and found that proliferation of mouse, zebrafish, and human α cells was mTOR and FoxP transcription factor dependent. Changes in hepatic amino acid (AA) catabolism gene expression predicted the observed increase in circulating AAs. Mimicking these AA levels stimulated α cell proliferation in a newly developed in vitro assay with L-glutamine being a critical AA. α cell expression of the AA transporter Slc38a5 was markedly increased in mice with interrupted glucagon signaling and played a role in α cell proliferation. These results indicate a hepatic α islet cell axis where glucagon regulates serum AA availability and AAs, especially L-glutamine, regulate α cell proliferation and mass via mTOR-dependent nutrient sensing.Entities:
Keywords: Slc38a5; alpha cell; amino acid; amino acid transport; glucagon; glucagon receptor; glutamine; liver; pancreatic islet; proliferation
Mesh:
Substances:
Year: 2017 PMID: 28591638 PMCID: PMC5572896 DOI: 10.1016/j.cmet.2017.05.011
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287